Recurrent Neuroblastoma Recruiting Phase 1 / 2 Trials for Aldesleukin (DB00041)

Also known as: Neuroblastoma Recurrent

IndicationStatusPhase
DBCOND0028756 (Recurrent Neuroblastoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02173093Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and OsteosarcomaTreatment